Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A...

Area of Science:

• Cardiovascular disease risk in oncology
• Biomarker analysis in cancer patients
• Oxidative stress and cardiovascular events

Background:

• Serum biomarkers are studied for cancer-related cardiovascular (CV) risk prediction.
• Current analysis often overlooks changes in biomarkers over time.
• Inflammatory and oxidative stress (OS) markers require further investigation for their association with CV events.

Purpose of the Study:

• To investigate the predictive role of longitudinal changes in serum biomarkers during cancer treatment.
• To assess commonly used and OS-related biomarkers for predicting CV events.

Main Methods:

• Observational study enrolling patients aged 75+ or younger with high CV risk.
• Biomarker assessment at baseline and during therapy.
• Utilized Cox models, Subpopulation Treatment-Effect Pattern Plot (STEPP), and repeated measures analysis.

Main Results:

• 182 patients enrolled; 168 evaluable, with 28 CV events over median 9.2 months follow-up.
• Elevated baseline fibrinogen (HR=3.95) and troponin (HR=2.48) were independent CV event risk factors.
• Increased D-dimer, blood pressure, and decreased ejection fraction observed over time in patients with CV events.

Conclusions:

• Higher baseline fibrinogen and troponin, and increasing D-dimer and blood pressure over time, correlate with increased CV risk in cancer patients.
• The study suggests a need for further assessment of oxidative stress's role in fibrinogen elevation.
• Longitudinal monitoring of D-dimer and blood pressure is recommended for cancer patients undergoing therapy.